Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp. PR Newswire NEW YORK, Feb. 21, 2019 NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp. PR Newswire NEW YORK, Feb. 21, 2019 NEW YORK, Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Feb. 21, 2019 SAN DIEGO...
Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71% ORR) Long-term Follow Up...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that...
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on...
New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design...
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約